Institutional members access full text with Ovid®

Share this article on:

Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/CT

Musto, Alessandraa,*; Grassetto, Gaiab,*; Marzola, Maria Cristinab; Rampin, Luciab; Chondrogiannis, Sotiriosb; Maffione, Anna Margheritab; Colletti, Patrick M.c; Perkins, Alan C.d,e; Fagioli, Giorgioa; Rubello, Domenicob

Nuclear Medicine Communications: June 2014 - Volume 35 - Issue 6 - p 588–597
doi: 10.1097/MNM.0000000000000091
Review Article

Epithelial ovarian carcinoma is a major form of cancer affecting women in the western world. The silent nature of this disease results in late presentation at an advanced stage in many patients. It is therefore important to assess the role of imaging techniques in the management of these patients. This article presents a review of the literature on the role of 18F-FDG-PET/CT in the different stages of management of epithelial ovarian cancer. Moreover, a comparison with other imaging techniques has been made and the relationship between 18F-PET/CT and the assay of serum CA-125 levels has been discussed.

aService of Nuclear Medicine, Maggiore Hospital, Bologna

bDepartment of Nuclear Medicine, PET/CT Centre, Santa Maria della Misericordia Hospital, Rovigo, Italy

cDepartment of Radiology, Los Angeles University, Los Angeles, California, USA

dImaging Sciences Unit, School of Medicine, University of Nottingham

eDepartment of Medical Physics and Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK

* Alessandra Musto and Gaia Grassetto contributed equally to the writing of this article.

Correspondence to Domenico Rubello, Department of Nuclear Medicine, PET/CT Centre Santa Maria della Misericordia Hospital, Rovigo, Via Tre Martiri 140, 45100 Rovigo, Italy Tel: +39 0425 394428; fax: +39 0425 39 4434; e-mail: domenico.rubello@libero.it

Received November 30, 2013

Accepted January 17, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins